18 September 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine Presents Major Economic Benefits at ICPIC

Analysis Presented at ICPIC 2025 Highlight Benefits of Steriwave Nasal Photodisinfection in Head-to-Head Comparisons with Octenisan and Mupirocin

·    70% SSI reduction in hip and knee arthroplasties using Steriwave at Mid Yorkshire Hospitals NHS Trust compared to using Octenisan nasal gel alone.

·    52% lower SSI incidence with Steriwave across surgical specialties in published literature compared to mupirocin.[[1]-[3]]

·    Over £190 million annual potential cost savings in UK based on York Health Economics Consortium (YHEC) findings.

Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies, presented groundbreaking data to the global infection control community earlier today at the 13th International Conference on Prevention & Infection Control (ICPIC) in Geneva, Switzerland. The oral presentation highlighted health economic analysis by the respected York Health Economics Consortium (YHEC) and real-world results from Mid Yorkshire Hospitals NHS Trust (MYHT), which together demonstrated improved outcomes with Steriwave nasal photodisinfection over existing nasal decolonisation therapies. Findings from the YHEC analysis suggest the UK could reduce surgical site infections (SSIs) by more than 40,000 annually and generate net saving of over £190 million each year.

Carolyn Cross, CEO of Ondine stated:

"This is a pivotal moment for patient safety. The data show Steriwave cuts infections and saves money-and because surgical site infections drive higher mortality, preventing them at scale could save thousands of lives across the UK each year."

The presentation detailed a universal presurgical nasal decolonisation protocol using a five-minute application of Steriwave immediately before surgery in a head-to-head comparison with Octenisan and mupirocin, topical antimicrobials currently being used to reduce nasal pathogens. The MYHT data show a 70% reduction in SSIs for total hip and knee arthroplasty patients using Steriwave photodisinfection with Octenisan compared to the Octenisan-only control group.

The health economic analysis by YHEC highlights the broader economic impact, finding a net saving of £38 to £107 per operation over mupirocin. Extrapolated over national surgical volumes and SSI rates, this projects a system-wide implementation of Steriwave could prevent over 40,000 SSIs in the UK annually and generate over £190 million in net annual savings by reducing hospital readmissions and extended patient stays.

Dr. Simon Sinclair, Chief Medical Officer of Ondine Biomedical commented:

"These results from independent third parties are highly encouraging and validate our mission to make this innovative technology a standard of care in surgical practice to improve outcomes. SSIs are among the most devastating and costly hospital-acquired infections. This evaluation confirms that Steriwave not only protects patients but also delivers substantial economic value. We believe it represents a scalable innovation for infection prevention at the health system level."

Ondine has a history of presenting its groundbreaking work at ICPIC, highlighting the versatility and efficacy of Steriwave across various clinical challenges:

·      2019: Presented findings on the successful use of Steriwave against the multidrug-resistant fungus, C. auris, achieving a >99.9% reduction in minutes.

·      2021: Presented on its successful application in reducing COVID-19 transmission, for which it received the prestigious ICPIC Innovation Excellence Award.

·      2023: Presented research demonstrating Steriwave's high effectiveness against extensively drug-resistant (XDR) gram-negative bacteria, achieving greater than a 99.99% kill rate in just 20 seconds. The research specifically highlighted the technology's effectiveness-a competitive advantage over topical antibiotics-against gram-negative bacteria such as E. coli, P. aeruginosa, E. cloacae, and K. pneumoniae, which are known to cause serious healthcare-associated infections.

SSIs are a major cause of hospital readmissions, adding an average of 9.7 extra days in hospital, requiring 45-75 additional staff hours per major case, and increasing the risk of mortality by 2-to 11-fold.[[4]] Steriwave's rapid, broad-spectrum action destroys pathogens, including multidrug-resistant bacteria, viruses and fungi in minutes, making resistance unlikely. Unlike traditional approaches that require patients to apply ointments at home for days, resulting in poor patient compliance and increasing resistance, Steriwave's rapid, single-use application improves patient compliance and offers a broad-spectrum defense against a wide range of multidrug-resistant pathogens.

A digital copy of the ICPIC 2025 poster is available here.

Enquiries:

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico, and several other countries under the name Steriwave^®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.